| 生物活性 |
Ochratoxin A (Phe-OTA) is an orally effective, blood-brain barrier-penetrating foodborne mycotoxin, a secondary metabolite of Aspergillus and Penicillium fungi, and a class 2B carcinogen that induces oxidative stress, inhibits mitochondrial respiration, causes oxidative DNA damage, disrupts the PPAR-γ-CD36 axis, induces immunosuppression, mediates mitochondrial-dependent apoptosis, inhibits glutamate uptake, triggers demyelinating lesions and neuroinflammation, leads to DNA hypomethylation, and inhibits cell proliferation, thereby inducing nephrotoxicity, hepatotoxicity, immunotoxicity, and neurotoxicity, and also exhibiting mutagenicity, teratogenicity, and carcinogenicity. |
体外研究 (In Vitro) |
Ochratoxin A (1-100 μM; 24 h) 可降低 SH-SY5Y 和 HT22 细胞的活力并增加 RONS 生成,在 HT22 细胞中诱导线粒体依赖性凋亡并改变蛋白质组表达,但对 SH-SY5Y 细胞的蛋白质组无显著影响。 Ochratoxin A (1 nM-100 μM; 24-72 h) 可抑制大鼠皮质星形胶质细胞的细胞外谷氨酸摄取,其 IC50 值分别为 1.3 μM 和 10.1 μM,作用机制为降低 GLAST 和 GLT-1 的细胞表面表达,而不改变转运体的总水平。 Ochratoxin A (2 nM-10 nM; 2-10 days) 可在大鼠三维全脑聚集培养物中诱导神经炎症、脱髓鞘以及神经元、少突胶质细胞和星形胶质细胞功能异常,其作用机制可能与 Sonic hedgehog 信号通路受损有关。 Ochratoxin A (1 nM-1 μM; 1-2 days) 会诱导 SH-SY5Y 细胞产生细胞毒性,并改变神经元维持基因的表达;而与人类每日食物摄入量相当的剂量 (2 fM, 20 fM; 11 days) 处理 11 天后,对基因表达无影响。 Ochratoxin A (10 nM, 20 nM; 24 h, 48 h) 可通过改变胶质细胞和炎症基因的表达,破坏无血清聚集大鼠脑细胞培养物中星形胶质细胞的细胞骨架完整性及神经保护性胶质反应模式。 Ochratoxin A (10 nM) 可通过破坏 Sonic hedgehog 信号通路,损伤成熟大鼠胚胎端脑三维聚集培养物中的 DNA 合成并改变发育及细胞周期相关基因的表达,但对未成熟培养物无影响。 Ochratoxin A (2.5-30 μM; 48 h) 可在 SHSY5Y 和 HT22 细胞中诱导氧化性 DNA 损伤及全基因组 DNA 低甲基化,在 15-30 μM 浓度下会导致 HT22 细胞出现染色体不稳定性,且大部分效应随时间推移具有可逆性。 Ochratoxin A (0.5-2 μM; 48 h) 可通过细胞周期阻滞、钙超载及促凋亡信号通路的激活,抑制 NHA-SV40LT 细胞的增殖并诱导其发生线粒体依赖性凋亡。 Ochratoxin A (31.25-2000 nM; 24 h) 可通过上调促炎细胞因子及介质的表达,在永生化小鼠小胶质细胞 BV-2 中诱导促炎反应。
Cell Viability Assay
| Cell Line: |
human dopamine-producing neuroblastoma SH-SY5Y cells, mouse hippocampal HT22 cells |
| Concentration: |
1, 10, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly decreased cell viability in both cell lines. Increased RONS production in both cell lines. Induced mitochondria-dependent apoptosis (caspase-3 activation and p53 phosphorylation) only in HT22 cells. Down-regulated 22 protein spots and up-regulated 17 protein spots in HT22 cells, including ornithine aminotransferase, nucleophosmin 1, valosin containing protein, peroxiredoxin 6, prohibitin, prolyl 4-hydroxylase, Atp5b protein, and eukaryotic translation elongation factor 1 delta isoform. Caused no significant proteome changes in SH-SY5Y cells. |
Real Time qPCR
| Cell Line: |
human neuroblastoma SH-SY5Y cells |
| Concentration: |
2 fM, 20 fM; 1 nM, 10 nM, 50 nM, 0.1 μM, 0.5 μM, 1 μM |
| Incubation Time: |
11 days (2 fM, 20 fM); 1 day, 2 days (1 nM, 10 nM, 50 nM, 0.1 μM, 0.5 μM, 1 μM) |
| Result: |
Did not modify expression of BDNF, MAPT, TPPP, BAX, or P53 at 2 fM and 20 fM for 11 days. Induced cytotoxicity and neuronal dysfunction at 1 nM to 1 μM. Decreased BDNF and TPPP expression at 1 μM at 1 day post-treatment but increased them at 2 days. Significantly decreased MAPT, BAX, and P53 expression at 1 μM at both 1 day and 2 days post-treatment. |
Cell Proliferation Assay
| Cell Line: |
normal human astrocyte (NHA-SV40LT) cells |
| Concentration: |
0.5, 1, 2 μM |
| Incubation Time: |
48 h |
| Result: |
Caused dose-dependent decreases in cell proliferation. Induced sub G0/G1 cell cycle arrest via down-regulation of CDK4, CCND1, CCNE1, and MYC. Increased cytosolic and mitochondrial calcium levels. Activated AKT, ERK1/2, and JNK signaling. Induced mitochondrial membrane potential loss. Up-regulated pro-apoptotic genes P53 and BAX, as well as MMP2 and PLAUR. |
Real Time qPCR
| Cell Line: |
immortalized mouse microglial BV-2 cells |
| Concentration: |
31.25, 62.5, 125, 250, 500, 1000, 2000 nM |
| Incubation Time: |
24 h |
| Result: |
Significantly increased mRNA expression of IL-6, TNF-α, IL-1β, and iNOS. Elevated NO and IL-6 concentrations in culture media. |
|
体内研究 (In Vivo) |
Ochratoxin A 可通过降低成熟 CD4+和 CD8+ T 细胞比例、抑制抗体产生诱导雌性 BALB/C 小鼠产生免疫抑制,而产后短期暴露则会刺激免疫应答。 Ochratoxin A 可诱导大鼠发生氧化应激介导的肾毒性,而线粒体重组含锰超氧化物歧化酶可缓解该毒性。 Ochratoxin A 可诱导近端肾小管脂质过氧化,进而导致猪患肾癌。 Ochratoxin A 可诱导鸭肝脏氧化损伤及脂质代谢功能紊乱,姜黄素可缓解其毒性。 Ochratoxin A (1.38-5.53 mg/kg;腹腔注射;单次给药) 短期暴露会导致成年斑马鱼出现运动障碍,同时伴随脑部的适应性抗氧化反应。 Ochratoxin A (0.25-0.5 µM;水体暴露;受精后 6-72 h) 在斑马鱼早期发育阶段暴露会引发剂量依赖性脑出血及脑血管/脑室缺陷。 Ochratoxin A (3.5-6 mg/kg;腹腔注射;单次给药) 急性暴露会增加小鼠脑区的氧化应激水平、耗竭纹状体多巴胺,并抑制氧化 DNA 修复,但不会诱导直接的神经元细胞死亡。 Ochratoxin A (3.0 ppm;日粮给药;妊娠第 6 天至出生后第 77 天) 的发育暴露会导致雄性大鼠后代海马神经发生短暂减少及神经化学改变,出生后第 77 天时无持续性影响。 Ochratoxin A (3.5 mg/kg;腹腔注射;3 天内累计给药 1 至 6 次) 急性暴露可呈剂量依赖性地损伤成年雄性小鼠海马齿状回中的星形胶质细胞结构并降低神经元存活率。 Ochratoxin A (3.5 mg/kg;腹腔注射;3 天内累计给药 1、2、3 或 6 次) 急性暴露可呈剂量依赖性降低成年雄性 Mus musculus脑室下区的细胞增殖水平、神经胶质细胞数量及神经元分化能力。 Ochratoxin A (0.21-0.5 mg/kg bw;口服;每日;28 天) 的亚慢性暴露会在 Balb/c 小鼠中诱导出持续性帕金森病样病理特征及精细运动功能损伤。 Ochratoxin A (10 mg/kg;口服;每日;连续 28 天) 亚慢性口服暴露会诱导大鼠脑组织产生氧化应激,但不会造成组织病理学损伤。 Ochratoxin A (289 µg/kg;口服;每日;4 周) 亚慢性口服暴露可下调大鼠海马 NMDA 受体亚基 NR2A 和 NR2B。 Ochratoxin A (3.5 mg/kg;腹腔注射;每日;连续 3 天) 急性暴露会诱导雄性小鼠出现帕金森样行为、神经递质耗竭、氧化应激及神经元凋亡通路抑制。
| Animal Model: |
Adult zebrafish |
| Dosage: |
1.38 mg/kg; 2.77 mg/kg; 5.53 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Induced locomotor impairment, with decreased mean speed, total distance traveled, and absolute turn angle, plus increased freezing time. Showed no effect on social interaction. Increased glutathione reductase, glutathione-S-transferase, and glutathione peroxidase activities in brain tissue. Decreased non-protein thiols level in brain tissue. Showed no change in lipid peroxidation level in brain tissue. |
| Animal Model: |
wild-type AB strain, double transgenic Tg(fli1a:EGFP; gata1:DsRed) (embryos) |
| Dosage: |
0.25 µM; 0.5 µM |
| Administration: |
water exposure; 6-72 h post fertilization |
| Result: |
Caused dose-dependent cerebral hemorrhage, most frequent in the hindbrain. Detected extravasated erythrocytes in hindbrain, midbrain, forebrain, and ventricular cranial interstitial spaces at the 0.5 µM dose. Impaired early brain ventricle development at the 0.5 µM dose, causing abnormal cavities, reduced tissue mass, and defective hindbrain organization. |
| Animal Model: |
Swiss ICR (male) |
| Dosage: |
3.5 mg/kg; up to 6 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Caused a dose-dependent reduction in striatal dopamine content and turnover at doses up to 6 mg/kg. Significantly decreased tyrosine hydroxylase immunoreactivity in striatal fibers, locus ceruleus cells, and substantia nigra cells at 72 h post-treatment with the 3.5 mg/kg dose. Increased superoxide dismutase activity, lipid peroxidation level, and oxidative DNA damage in all investigated brain regions (hippocampus, cerebral cortex, cerebellum, midbrain, pons/medulla, caudate/putamen). Induced transient inhibition of oxidative DNA repair at 6 h post-treatment. Showed no cell death or changes in dopamine and cyclic AMP regulated phosphoprotein (DARPP32) levels. |
| Animal Model: |
Sprague Dawley (male offspring) |
| Dosage: |
0.12 ppm; 0.6 ppm; 3.0 ppm |
| Administration: |
dietary; gestation day 6 to postnatal day 77 |
| Result: |
Significantly decreased hippocampal neurogenesis-related indices in male postnatal day 21 offspring at the 3.0 ppm dose, including reduced type-2 progenitor cells (PAX6+ or TBR2+), decreased hilar GABAergic interneurons (SST+ or CHRNB2+), down-regulated cholinergic signaling, and increased malondialdehyde accumulation in the subgranular zone of the dentate gyrus. Significantly increased mRNA expression of neurotrophin (Bdnf), serotonergic receptors (Tph2, Htr1a, Htr4), serotonin-synthesizing enzyme, and glutamatergic receptors (Gria1, Gria2, Grin2a) in the dentate gyrus at the 3.0 ppm dose. Showed no developmental gait abnormalities or brain histopathology at any dose on postnatal day 21 or 77. Showed no neurochemical changes at postnatal day 77. |
| Animal Model: |
C57BL/6 (male) |
| Dosage: |
3.5 mg/kg |
| Administration: |
i.p.; 1 to 6 cumulative doses over 3 days |
| Result: |
Caused a dose-dependent, significant reduction in astrocyte branch length and number, GFAP cell expression, astrocyte quantity, young neuron count, and mature neuron count in the hippocampal dentate gyrus. |
| Animal Model: |
C57BL/6 (adult male) |
| Dosage: |
3.5 mg/kg |
| Administration: |
i.p.; 1, 2, 3, or 6 cumulative doses over 3 days |
| Result: |
Caused a dose-dependent decrease in cellular proliferation, astrocyte count (reduced GFAP immunostaining), microglia count (reduced Iba1 immunostaining), young neuron count (reduced doublecortin immunostaining), beta III tubulin (TUJ1) cell count, and calretinin+ cell count in the subventricular zone. |
| Animal Model: |
Balb/c |
| Dosage: |
0.21 mg/kg bw; 0.5 mg/kg bw |
| Administration: |
p.o.; daily; 28 days |
| Result: |
Significantly impaired fine motor function (wire hang and negative geotaxis tests) despite no overt clinical toxicity, unchanged body weight, and undetectable ochratoxin A in plasma and brain tissue after the 6-month recovery period. Induced loss of striatal dopaminergic innervation, dopaminergic cell dysfunction, increased phosphorylated alpha-synuclein levels, and a dose-dependent decrease in lysosome-associated membrane protein type 2 A (LAMP-2A) level in the midbrain. Showed no effect on hsc70 protein level. |
| Animal Model: |
Rats |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; daily; 28 days |
| Result: |
Caused a significant decrease in brain glutathione level and superoxide dismutase activity. Caused significant increases in brain catalase activity, glutathione reductase activity, and malondialdehyde level. Showed no histopathological brain injury. |
| Animal Model: |
Rats |
| Dosage: |
289 µg/kg |
| Administration: |
p.o.; daily; 4 weeks |
| Result: |
Significantly decreased protein expression levels of hippocampal N-methyl-D-aspartate (NMDA) receptor subunits NR2A and NR2B. |
| Animal Model: |
Male mice |
| Dosage: |
3.5 mg/kg |
| Administration: |
i.p.; daily; 3 consecutive days |
| Result: |
Induced Parkinsonian physiognomies, including impaired performance in spontaneous activity, gait analysis, pole test, and cylinder tests. Caused significant reductions in whole brain, hippocampus, and striatum levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin (5-HT), norepinephrine, 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA). Increased oxidative stress. Inhibited neuronal apoptosis pathways (PI3K/AkT signaling) and Fork head box (FOXO) transcriptional activity. Caused brain histopathological injuries. |
|
| 性状 |
固体 |
| 颜色 |
White to off-white |